Evidence map›Paper›PMID 38770087›Full record

ArticleFrontiers in chemical biology2024

An

Celeste Huaman, Caitlyn Clouse, Madeline Rader, Lianying Yan, Shuangyi Bai, Bronwyn M Gunn, Moushimi Amaya, Eric D Laing, Christopher C Broder, Brian C Schaefer

Abstract read
In one paragraph

Article in Frontiers in chemical biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Viruses · 2024
    Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Celeste HuamanDepartment of Microbiology and Immunology, Uniformed Services University, Bethesda, MD, USA.
Caitlyn ClouseDepartment of Microbiology and Immunology, Uniformed Services University, Bethesda, MD, USA.
Madeline RaderDepartment of Microbiology and Immunology, Uniformed Services University, Bethesda, MD, USA.
Lianying YanDepartment of Microbiology and Immunology, Uniformed Services University, Bethesda, MD, USA.
Shuangyi BaiPaul G. Allen School of Global Health, College of Veterinary Medicine, Washington State University, Pullman WA 99164 USA.
Bronwyn M GunnPaul G. Allen School of Global Health, College of Veterinary Medicine, Washington State University, Pullman WA 99164 USA.
Moushimi AmayaDepartment of Microbiology and Immunology, Uniformed Services University, Bethesda, MD, USA.
Eric D LaingDepartment of Microbiology and Immunology, Uniformed Services University, Bethesda, MD, USA.
Christopher C BroderDepartment of Microbiology and Immunology, Uniformed Services University, Bethesda, MD, USA.
Brian C SchaeferDepartment of Microbiology and Immunology, Uniformed Services University, Bethesda, MD, USA.

Funding

Vaccine strategy for broad spectrum protection agains non-typhoidal salmonellU54AI057168 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI GEDDES, CHRISTOPHER DARREN · 2003 to 2013
$91.5M
Project 3 - USUHSU19AI142764 · NIAID · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI ELDRIDGE, JOHN HAYWARD · 2019 to 2023
$24.6M
T cell receptor-activated autophagy as a regulator of T cell effector responsesR01AI125552 · NIAID · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI CONRADS, THOMAS PATRICK, HE, YOU-WEN · 2017 to 2021
$3.1M
NIAID NIH HHS R01 AI125552NIAID NIH HHS U19 AI142764NIAID NIH HHS U54 AI057168
6 · The paper itself

Abstract

Henipaviruses are enveloped single-stranded, negative-sense RNA viruses of the paramyxovirus family. Two henipaviruses, Nipah virus and Hendra virus, cause a systemic respiratory and/or neurological disease in humans and ten additional species of mammals, with a high fatality rate. Because of their highly pathogenic nature, Nipah virus and Hendra virus are categorized as BSL-4 pathogens, which limits the number and scope of translational research studies on these important human pathogens. To begin to address this limitation, we are developing a BSL-2 model of authentic henipavirus infection in mice, using the non-pathogenic henipavirus, Cedar virus. Notably, wild-type mice are highly resistant to Hendra virus and Nipah virus infection. However, previous work has shown that mice lacking expression of the type I interferon receptor (IFNAR-KO mice) are susceptible to both viruses. Here, we show that luciferase-expressing recombinant Cedar virus (rCedV-luc) is also able to replicate and establish a transient infection in IFNAR-KO mice, but not in wild-type mice. Using longitudinal bioluminescence imaging (BLI) of luciferase expression, we detected rCedV-luc replication as early as 10 h post-infection. Viral replication peaks between days 1 and 3 post-infection, and declines to levels undetectable by BLI by 7 days post-infection. Immunohistochemistry is consistent with viral infection and replication in endothelial cells and other non-immune cell types within tissue parenchyma. Serology analyses demonstrate significant IgG responses to the Cedar virus surface glycoprotein with potent neutralizing activity in IFNAR-KO mice, whereas antibody responses in wild-type animals were non-significant. Overall, these data suggest that rCedV-luc infection of IFNAR-KO mice represents a viable platform for the study of

Indexed as

Cedar virusfirefly luciferaseHendra virushenipavirusIFNAR−/− miceNipah virusparamyxoviruspre-clinical model

Identifiers

PMID38770087
PMCPMC11105800

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.